- Home
- RVPHW vs BMRN Comparison
RVPHW vs BMRN Comparison
Compare RVPHW & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- BMRN
- Stock Information
- Founded
- RVPHW 2018
- BMRN 1996
- Country
- RVPHW United States
- BMRN United States
- Employees
- RVPHW N/A
- BMRN N/A
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- RVPHW Health Care
- BMRN Health Care
- Exchange
- RVPHW Nasdaq
- BMRN Nasdaq
- Market Cap
- RVPHW N/A
- BMRN N/A
- IPO Year
- RVPHW N/A
- BMRN 1999
- Fundamental
- Price
- RVPHW $0.12
- BMRN $68.25
- Analyst Decision
- RVPHW
- BMRN Buy
- Analyst Count
- RVPHW 0
- BMRN 21
- Target Price
- RVPHW N/A
- BMRN $93.80
- AVG Volume (30 Days)
- RVPHW 22.4K
- BMRN 1.5M
- Earning Date
- RVPHW 03-14-2025
- BMRN 02-19-2025
- Dividend Yield
- RVPHW N/A
- BMRN N/A
- EPS Growth
- RVPHW N/A
- BMRN 154.02
- EPS
- RVPHW N/A
- BMRN 2.21
- Revenue
- RVPHW N/A
- BMRN $2,853,915,000.00
- Revenue This Year
- RVPHW N/A
- BMRN $18.88
- Revenue Next Year
- RVPHW N/A
- BMRN $10.12
- P/E Ratio
- RVPHW N/A
- BMRN $30.88
- Revenue Growth
- RVPHW N/A
- BMRN 17.97
- 52 Week Low
- RVPHW $0.13
- BMRN $60.63
- 52 Week High
- RVPHW $0.15
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- BMRN 65.25
- Support Level
- RVPHW N/A
- BMRN $63.55
- Resistance Level
- RVPHW N/A
- BMRN $70.50
- Average True Range (ATR)
- RVPHW 0.00
- BMRN 1.76
- MACD
- RVPHW 0.00
- BMRN 0.59
- Stochastic Oscillator
- RVPHW 0.00
- BMRN 74.40
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.